TY  - JOUR

T1  - Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.

JO  - Eur Heart J

PY  - 1998/04/01

AU  - van Hout BA

AU  - Bowman L

AU  - Zelinger DJ

AU  - Simoons ML

ED  - 

VL  - 19 Suppl D

SP  - D59

EP  - D66

Y2  - 2024/12/22

ER  -